University of North Carolina, Chapel Hill
University of North Carolina, Chapel Hill sponsors 1,109 registered US clinical trials on ClinicalTrials.gov, 108 of them currently recruiting, and 881 completed. 69 of these trials are in Phase 3-4 (later-stage) and 203 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 17 trials.
Trial Pipeline
1,109 total, page 23 of 23
Atypical Antipsychotic Treatment Effect On Brain Function In Schizophrenia Measured By FMRI
NCT01234454
Sensory Re-Training Following Facial Surgery for Correction of Facial Skeletal Disharmony
NCT00078507
Assessing the Results of Lip Surgery in Patients With Cleft Lip and Palate
NCT00070811
GIOP Prevention Among People With Rheumatoid Arthritis
NCT00609830
Cognitive Therapy for Binge-Eating Disorder
NCT00050037
Development and Evaluation of a Medical Intervention for Early Childhood Caries
NCT00464009
A Church Based Intervention to Improve Diabetes Care
NCT00311324
Antiphospholipid Syndrome Collaborative Registry (APSCORE)
NCT00076713
COMBINE (Acamprosate/Naltrexone)
NCT00006206
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 111 |
| Phase 2 | 92 |
| Phase 3 | 13 |
| Phase 4 | 56 |
Therapeutic Areas
What the Pipeline for University of North Carolina, Chapel Hill Shows
According to the ClinicalTrials.gov registry, University of North Carolina, Chapel Hill is linked to 1,109 US clinical trials across every stage of research activity. Of those, 108 studies are currently recruiting, about 10% of the sponsor's indexed portfolio, and 881 are already marked complete, representing roughly 79% of the total.
The phase mix for University of North Carolina, Chapel Hill reports 69 late-stage studies (Phase 3 and Phase 4 combined) and 203 earlier-phase studies (Phase 1 and Phase 2).
The top therapeutic focus area indexed for University of North Carolina, Chapel Hill is Obesity with 17 linked trials, and 9 other condition areas appear in the top list above.
How to read these pipeline numbers
Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.